The atopic dermatitis (AD) therapeutic landscape is expanding rapidly, driven by rising prevalence – roughly  26 million individuals in the US have AD – greater diagnostic awareness, and heightened demand for treatments that extend beyond temporary symptom relief to address long-term disease control and quality of life factors. While the clinical research pipeline for AD looks promising, the path to innovation is hindered by persistent barriers to trial enrollment.